Thomas W. Dubensky

11.2k citations

99 papers · 7.8k indexed · 3 hit papers · h-index 43

Immunology top 0.2%
Molecular Biology top 2%
Oncology top 1%
Infectious Diseases top 0.5%
Genetics top 1%

Co-authors: Sarah M. McWhirter Leticia Corrales David B. Kanne Thomas F. Gajewski Dirk G. Brockstedt Edward E. Lemmens Kelsey E. Sivick Meredith L. Leong
Topics: Immunotherapy and Immune Responses (32 papers)Virus-based gene therapy research (23 papers)interferon and immune responses (18 papers)
Cited by: Immunology Infectious Diseases Biotechnology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation Nature Medicine
Partner nations: United States Japan France

In The Last Decade

Thomas W. Dubensky

99 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

2015 1.1k citations Laura Hix Glickman, Sarah M. McWhirter et al. Cell Reports profile →
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

2015 581 citations David B. Kanne, Meredith L. Leong et al. profile →
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021 240 citations Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Thomas W. Dubensky

Since Specialization

Citations

This map shows the geographic impact of Thomas W. Dubensky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. Dubensky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. Dubensky more than expected).

Fields of papers citing papers by Thomas W. Dubensky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas W. Dubensky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. Dubensky. The network helps show where Thomas W. Dubensky may publish in the future.

Co-authorship network of co-authors of Thomas W. Dubensky

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas W. Dubensky. A scholar is included among the top collaborators of Thomas W. Dubensky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas W. Dubensky. Thomas W. Dubensky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors 2024 ·Cancer Research Communications ·Mark Yarchoan,John D. Powderly,Bruno R. Bastos,Thomas B. Karasic,Oxana Crysler,Pamela N. Münster,Meredith McKean,Leisha A. Emens,Yvonne M. Saenger,Yasser Ged,Robert Stagg,Steven Smith,Chan C. Whiting,(unknown),Peppi Prasit,(unknown),Nathan Standifer,Thomas W. Dubensky,Sam H. Whiting,Susanna V. Ulahannan	11
2	Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors 2023 ·Cancer Research Communications ·Brian J. Francica,Anja Holtz,Justine Lopez,David Freund,(unknown),Dingzhi Wang,David Powell,Franciele Kipper,Dipak Panigrahy,Raymond N. DuBois,Chan C. Whiting,Peppi Prasit,Thomas W. Dubensky	20
3	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomasbreakdown → 2021 ·Clinical Cancer Research ·Funda Meric‐Bernstam,Randy F. Sweis,F. Stephen Hodi,Wells A. Messersmith,Robert H.I. Andtbacka,Matthew Ingham,Nancy Lewis,Xinhui Chen,Marc R. Pelletier,Xueying Chen,Jincheng Wu,Thomas W. Dubensky,Sarah M. McWhirter,Thomas Müller,Nitya Nair,Jason J. Luke	240
4	TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors 2018 ·Cancer Immunology Research ·Brian J. Francica,Ali Ghasemzadeh,Anthony L. Desbien,Debebe Theodros,Kelsey E. Sivick,Gabrielle L. Reiner,Laura Hix Glickman,Ariel E. Marciscano,Andrew B. Sharabi,Meredith L. Leong,Sarah M. McWhirter,Thomas W. Dubensky,Drew M. Pardoll,Charles G. Drake	67
5	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer 2018 ·JCI Insight ·(unknown),Alexander C. Hopkins,Eric R. Lutz,Annie A. Wu,Mark Yarchoan,Kayla Cruz,Skylar Woolman,Teena Vithayathil,Laura Hix Glickman,Chudi Ndubaku,Sarah M. McWhirter,Thomas W. Dubensky,Todd D. Armstrong,Elizabeth M. Jaffee,Neeha Zaidi	132
6	STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection 2018 ·Cell Reports ·Erik Van Dis,Kimberly M. Sogi,Chris S. Rae,Kelsey E. Sivick,Natalie H. Surh,Meredith L. Leong,David B. Kanne,Ken Metchette,Justin J. Leong,(unknown),Vivian Hsueh Hua Chen,Kartoosh Heydari,Nathalie Cadieux,Tom Evans,Sarah M. McWhirter,Thomas W. Dubensky,Daniel A. Portnoy,Sarah A. Stanley	91
7	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). 2017 ·Journal of Clinical Oncology ·Dung T. Le,Andrew H. Ko,Zev A. Wainberg,Vincent J. Picozzi,Hedy L. Kindler,Andrea Wang‐Gillam,Paul E. Oberstein,Michael A. Morse,Herbert J. Zeh,Colin D. Weekes,Tony R. Reid,Aimee Murphy,(unknown),Chan C. Whiting,Nitya Nair,Amanda Enstrom,Sandy Ferber,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee	39
8	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice 2017 ·Cancer Immunology Research ·Jeremy B. Foote,Marleen Kok,James M. Leatherman,Todd D. Armstrong,(unknown),Laureen S. Ojalvo,David B. Kanne,Elizabeth M. Jaffee,Thomas W. Dubensky,Leisha A. Emens	117
9	Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors 2015 ·Cancer Research ·Jason R. Baird,David J. Friedman,Benjamin Cottam,Thomas W. Dubensky,David B. Kanne,Shelly Bambina,Keith S. Bahjat,Marka R. Crittenden,Michael J. Gough	201
10	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination 2015 ·Clinical Cancer Research ·Christopher M. Jackson,Christina M. Kochel,Christopher J. Nirschl,Nicholas M. Durham,Jacob Ruzevick,Angela Alme,Brian J. Francica,(unknown),Andrew Daniels,Thomas W. Dubensky,Peter Lauer,Dirk G. Brockstedt,Emily G. Baxi,Peter A. Calabresi,Janis M. Taube,Carlos A. Pardo,Henry Brem,Drew M. Pardoll,Michael Lim,Charles G. Drake	54
11	Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity 2008 ·Proceedings of the National Academy of Sciences ·Gregory Crimmins,Anat A. Herskovits,Kai Rehder,Kelsey E. Sivick,Peter Lauer,Thomas W. Dubensky,Daniel A. Portnoy	86
12	Activation of Immature Hepatic NK Cells As Immunotherapy for Liver Metastatic Disease 2007 ·The Journal of Immunology ·Keith S. Bahjat,Rodney A. Prell,Heather E. Allen,Weiqun Liu,Edward E. Lemmens,Meredith L. Leong,Daniel A. Portnoy,Thomas W. Dubensky,Dirk G. Brockstedt,Martin Giedlin	21
13	Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes 2006 ·Cancer Research ·Kiyoshi Yoshimura,Ajay Jain,Heather E. Allen,(unknown),Christina Y. Chia,Sowmya Ravi,Dirk G. Brockstedt,Martin Giedlin,Keith S. Bahjat,Meredith L. Leong,Jill E. Slansky,David N. Cook,Thomas W. Dubensky,Drew M. Pardoll,Richard D. Schulick	48
14	Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity 2006 ·Nature Medicine ·Camie W. Chan,(unknown),(unknown),(unknown),Kiyoshi Yoshimura,Mario Škarica,Dirk G. Brockstedt,Thomas W. Dubensky,Monique F. Stins,Lewis L. Lanier,Drew M. Pardoll,Franck Housseau	318
15	Listeria monocytogenes as a Vaccine Vector: Virulence Attenuation or Existing Antivector Immunity Does Not Diminish Therapeutic Efficacy 2004 ·The Journal of Immunology ·(unknown),Kevin W. Bruhn,Hao Shen,Ronald A. Barry,Thomas W. Dubensky,Dirk G. Brockstedt,David J. Hinrichs,Darren E. Higgins,(unknown),Martin Giedlin,H. G. Archie Bouwer	74
16	Virus-based vectors for human vaccine applications 2002 ·Drug Discovery Today ·John M. Polo,Thomas W. Dubensky	38
17	Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways 2002 ·Nature Medicine ·Wolfgang W. Leitner,Leroy N. Hwang,Michael DeVeer,Aimin Zhou,Robert H. Silverman,Bryan Williams,Thomas W. Dubensky,Ying Han,Nicholas P. Restifo	232
18	(Re-)Engineering tumor cell-selective replicating adenoviruses: A step in the right direction toward systemic therapy for metastatic disease 2002 ·Cancer Cell ·Thomas W. Dubensky	15
19	Virus-mediated killing of cells that lack p53 activity 2001 ·Drug Resistance Updates ·John Nemunaitis,Neil Senzer,Casey Cunningham,Thomas W. Dubensky	9
20	Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect 1999 ·Journal of Clinical Investigation ·Guoshun Wang,Vladimir Slepushkin,Joseph Zabner,Shaf Keshavjee,Julie Johnston,Sybille L. Sauter,Doug J. Jolly,Thomas W. Dubensky,Beverly L. Davidson,Paul B. McCray	134

About Thomas W. Dubensky

Thomas W. Dubensky is a scholar working on Biotechnology, Immunology and Infectious Diseases, having authored 99 papers that have together received 7.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (32 papers), Virus-based gene therapy research (23 papers) and interferon and immune responses (18 papers). The work is most often cited by research in Immunology (4.8k citations), Infectious Diseases (1.8k citations) and Biotechnology (771 citations). Thomas W. Dubensky has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Sarah M. McWhirter, Leticia Corrales, David B. Kanne, Thomas F. Gajewski, Dirk G. Brockstedt, Edward E. Lemmens, Kelsey E. Sivick, Meredith L. Leong, Laura Hix Glickman and Justin J. Leong. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact